EvaLuAtion On the cHaracteristics of the True/False lUmen and Its Prognostic Value for cOronary C… (NCT04965207) | Clinical Trial Compass
UnknownNot Applicable
EvaLuAtion On the cHaracteristics of the True/False lUmen and Its Prognostic Value for cOronary CTO Patients Just Before Stent Implantation
1,000 participantsStarted 2021-10-01
Plain-language summary
IVUS will be used to evaluate the ratio of false lumen to occluded segment, the ratio of false lumen to stent length, the location characteristics of false lumen and its prognostic value for perioperative complications, 1-year late lumen loss and MACCE events in patients with coronary CTO.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 18 to 80 years old;
* be diagnosed with CTO;
* CTO located in an epicardial coronary artery with a reference diameter of ≥ 2.5mm;
* comply with all the evaluations and follow-up protocols.
Exclusion Criteria:
* suffered from acute myocardial infarction within the previous 3 months;
* rheumatic valvular disease;
* severe arrhythmia;
* lesions unsuitable for PCI;
* severely abnormal hematopoietic systems, such as platelet counts \<100\*10\^9/L or \> 700\*10\^9/L and white blood cell counts \< 3\*10\^9/L;
* with active bleeding or bleeding tendencies(active ulcers, short-term ischemic stroke, history of hemorrhagic stroke, intracranial space occupying lesions, recent craniocerebral trauma, and other bleeding or bleeding tendency);
* severe coexisting conditions, including severe renal function dysfunction \[Glomerular filtration rate less than 60ml/min • 1.73 m2), severe hepatic dysfunction \[glutamic-pyruvic transaminase (ALT) or glutamic-oxal acetic transaminase (ALT) elevated more than three times that of the upper limit of the normal reference\], severe heart failure (NYHA classification III-IV), acute infectious diseases and immune disorders; tumors; surgery within 3 months;
* a life expectancy less than 12 months;
* pregnancy or planning to become pregnant;
* history of allergy or adverse reactions to aspirin, clopidogrel, ticagrelor, stains, contrast material, anticoagulant, or stents;
* cannot tolerate dual antiplatelet treatment;
* unable to com…